Syneos Health Inc. ($SYNH) Stock Forecast: Up 7.4% Today

What is Syneos Health Inc.?

SYNH is a contract research organization that provides clinical and commercial solutions to biopharmaceutical companies.

Why is Syneos Health Inc. going up?

SYNH stock is up 7.4% on May 10, 2023 12:25

• SYNH had a strong bullish movement after reporting better-than-expected Q1 earnings.
• Q1 Non-GAAP EPS of $0.75 beat estimated earnings by $0.09, and revenue of $1.36B beat by $80M.
• The positive earnings report was likely due to increased net new business awards and bookings in their Clinical Solutions segment.
• The recent announcement of an investment consortium buying SYNH in a $7.1 billion deal may also be contributing to the bullish movement.

SYNH Price Chart

SYNH Technical Analysis

SYNH News

Syneos Health Non-GAAP EPS of $0.75 beats by $0.09, revenue of $1.36B beats by $80M

Syneos Health press release (SYNH): Q1 Non-GAAP EPS of $0.75 beats by $0.09.Revenue of $1.36B (+1.5% Y/Y) beats by $80M.Adjusted EBITDA of $151.1 million for the three months…

https://seekingalpha.com/news/3968963-syneos-health-non-gaap-eps-of-075-beats-by-009-revenue-of-136b-beats-by-80m

Syneos Health: Q1 Earnings Insights

Syneos Health (NASDAQ: SYNH ) reported its Q1 earnings results on Wednesday, May 10, 2023 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Syneos Health beat estimated earnings by 13.64%, reporting an EPS of $0.75 versus an … Full story available on Benzinga.com

https://www.benzinga.com/news/earnings/23/05/32311901/syneos-health-q1-earnings-insights

Syneos Health, Inc.: Syneos Health Reports First Quarter 2023 Results

Revenue for the first quarter of $1,356.8 million increased 1.5% on a reported basis and increased 2.4% on a constant currency basis year-over-year.Clinical Solutions net new business awards and bo…

https://www.finanznachrichten.de/nachrichten-2023-05/59047662-syneos-health-inc-syneos-health-reports-first-quarter-2023-results-399.htm

Syneos Health Reports First Quarter 2023 Results

MORRISVILLE, N.C., May 10, 2023 ( GLOBE NEWSWIRE ) -- Syneos Health ( Nasdaq:SYNH ) , a leading fully integrated biopharmaceutical solutions organization, today reported financial results for the three months ended March 31, 2023.

https://www.globenewswire.com/news-release/2023/05/10/2665412/33420/en/Syneos-Health-Reports-First-Quarter-2023-Results.html

Investment consortium to buy Syneos Health in $7.1 bln deal

May 10 ( Reuters ) - An investment consortium, comprising of Elliott Investment Management, Patient Square Capital and Veritas Capital, has agreed to buy Syneos Health Inc ( SYNH.O ) , in a deal valued at $7.1 billion, including debt, the contract research firm said on Wednesday.

https://www.reuters.com/markets/deals/investment-consortium-buy-syneos-health-71-bln-deal-2023-05-10/

Trending Today

Qualys Inc. ($QLYS) Stock Forecast: Up 5.3% Today

Stox ($STX) Crypto Forecast: Up 5.5% Today

CRISPR Therapeutics AG ($CRSP) Stock Forecast: Down 5.6% Today

Dollar Tree Inc. ($DLTR) Stock Forecast: Down 5.0% Today

Groupon Inc. ($GRPN) Stock Forecast: Up 6.2% Today

Upstart Holdings Inc. ($UPST) Stock Forecast: Up 5.0% Today

Cummins Inc. ($CMI) Stock Forecast: Up 6.0% Today

Algorand ($ALGO) Crypto Forecast: Up 5.3% Today

Cosmos ($ATOM) Crypto Forecast: Up 5.1% Today

SNDL Inc. ($SNDL) Stock Forecast: Up 5.3% Today

Syneos Health Inc. Price History

10.04.2023 - SYNH Stock was up 7.4%

• SYNH had a strong bullish movement after reporting better-than-expected Q1 earnings.
• Q1 Non-GAAP EPS of $0.75 beat estimated earnings by $0.09, and revenue of $1.36B beat by $80M.
• The positive earnings report was likely due to increased net new business awards and bookings in their Clinical Solutions segment.
• The recent announcement of an investment consortium buying SYNH in a $7.1 billion deal may also be contributing to the bullish movement.

10.04.2023 - SYNH Stock was up 7.5%

• SYNH's stock soared 9% in premarket trade after it announced its acquisition by a private investment consortium for about $7.1 billion in cash, which represents a 24% premium over the stock's closing price on Feb. 13.
• The consortium of Elliott Investment Management, Patient Square Capital, and Veritas Capital will buy SYNH, and the deal is expected to close in the second half of the year.
• The acquisition news has caused the bullish movement in SYNH's stock as investors are optimistic about the company's future growth prospects under the new ownership.